Levetiracetam Sun (Levetiracetam)

Levetiracetam is an antiepileptic drug used to control various seizure types by stabilizing neuronal activity.

• Partial seizures: Reduces frequency and severity of focal onset seizures, improving neurological stability.
• Generalized tonic‑clonic seizures: Contributes to seizure freedom or marked reduction in convulsive episodes, supporting overall seizure control.
• Myoclonic seizures: Diminishes rapid jerking movements characteristic of myoclonic epilepsy, aiding functional improvement.

• Levetiracetam binds selectively to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates vesicle exocytosis, decreasing abnormal neuronal firing and reducing excitatory synaptic transmission. By stabilizing neuronal membranes without directly affecting ion channels or G‑protein pathways, the drug provides broad antiepileptic activity across multiple seizure types. The precise downstream effects remain under investigation, but the overall result is a lowered propensity for seizure generation.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Fatigue: Persistent tiredness that may affect daily activities.
• Dizziness: Light‑headedness or vertigo, especially when standing quickly.
• Headache: Moderate cranial pain that can be throbbing or pressure‑like.
• Nausea: Stomach upset often accompanied by an urge to vomit.

Serious or Rare Side Effects

• Severe allergic reaction: Rash, facial swelling, or breathing difficulty suggesting anaphylaxis.
• Mood changes: New or worsening depression, suicidal ideation, or aggressive behavior.
• Blood disorders: Low platelet or neutrophil counts leading to bruising or infection susceptibility.
• Multiorgan hypersensitivity: Rare syndrome with fever, widespread rash, and potential organ involvement.

When using Levetiracetam intravenously, several precautions should be observed to ensure patient safety and product integrity.

• Renal function: Adjust dosing in patients with impaired kidney function.
• Hepatic status: Monitor liver enzymes in patients with hepatic disease.
• Concomitant antiepileptics: Assess for additive CNS effects when combined with other seizure medications.
• Pregnancy and lactation: Use only if potential benefit outweighs unknown risks.
• Behavioral monitoring: Observe for mood alterations or suicidal thoughts during therapy.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Carbamazepine: May reduce levetiracetam plasma levels, decreasing seizure control.
• Phenobarbital: Potential to lower levetiracetam concentrations, requiring close monitoring.
• Rifampicin: Strong enzyme inducer that can markedly decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely)

• Sedatives (benzodiazepines, opioids): Additive CNS depression may increase drowsiness.
• Antidepressants (SSRIs, SNRIs): Possible enhancement of behavioral side effects.
• Immunosuppressants (cyclosporine, tacrolimus): May require therapeutic drug monitoring.